Magnesium trisilicate
Magnesium trisilicate is a magnesium-containing antacid used for the symptomatic relief of dyspepsia and heartburn, commonly formulated with other antacids.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
It neutralises gastric acid and reacts with it to form silica gel, which can provide a degree of mucosal protection.
Prescribing in practice
- Magnesium salts may accumulate in renal impairment, so use with caution and avoid in significant renal failure.
- As a magnesium-based antacid it tends to have a laxative effect and is often combined with constipating aluminium salts.
- Antacids can interfere with the absorption of other medicines, so separate dosing from interacting drugs.
Monitoring
Routine monitoring is not required for occasional use, but consider renal function in patients with impairment or regular magnesium-containing antacid use.
Counselling the patient
- Take it for symptom relief and space it apart from your other medicines.
- Tell your clinician if you have kidney problems or if indigestion does not settle.
Evidence & guidelines
Antacids such as magnesium trisilicate are an established option for the symptomatic relief of dyspepsia in line with NICE guidance.
Reference: Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Lower Gastrointestinal Bleed · BSG 2019; NICE NG141
- Variceal Upper GI Bleed · BSG 2015; Baveno VII (2022)
- Spontaneous Bacterial Peritonitis (SBP) · BSG / EASL 2018
- Hepatorenal Syndrome · EASL 2018; ICA 2015
- Hepatic Encephalopathy · EASL 2014; West Haven criteria
- Clostridioides difficile Colitis · NICE NG199 (2021); IDSA/SHEA 2021